Biomerica (NASDAQ:BMRA – Get Free Report) and Anteris Technologies Global (NASDAQ:AVR – Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, earnings, valuation, profitability, risk and dividends.
Analyst Ratings
This is a summary of current ratings and price targets for Biomerica and Anteris Technologies Global, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Biomerica | 1 | 0 | 0 | 0 | 1.00 |
| Anteris Technologies Global | 1 | 1 | 3 | 0 | 2.40 |
Biomerica currently has a consensus target price of $9.00, indicating a potential upside of 496.03%. Anteris Technologies Global has a consensus target price of $14.00, indicating a potential upside of 125.81%. Given Biomerica’s higher probable upside, research analysts plainly believe Biomerica is more favorable than Anteris Technologies Global.
Valuation and Earnings
This table compares Biomerica and Anteris Technologies Global”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Biomerica | $4.45 million | 1.05 | -$3.78 million | ($1.64) | -0.92 |
| Anteris Technologies Global | $1.91 million | 316.46 | -$94.14 million | ($1.95) | -3.18 |
Biomerica has higher revenue and earnings than Anteris Technologies Global. Anteris Technologies Global is trading at a lower price-to-earnings ratio than Biomerica, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Biomerica and Anteris Technologies Global’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Biomerica | -115.50% | -142.81% | -77.83% |
| Anteris Technologies Global | -4,637.48% | -61.24% | -54.97% |
Risk and Volatility
Biomerica has a beta of 0.4, meaning that its stock price is 60% less volatile than the S&P 500. Comparatively, Anteris Technologies Global has a beta of 2.02, meaning that its stock price is 102% more volatile than the S&P 500.
Institutional & Insider Ownership
22.3% of Biomerica shares are held by institutional investors. 12.3% of Biomerica shares are held by company insiders. Comparatively, 4.5% of Anteris Technologies Global shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Summary
Biomerica beats Anteris Technologies Global on 7 of the 13 factors compared between the two stocks.
About Biomerica
Biomerica, Inc. is a medical diagnostics company that develops, manufactures and commercializes products designed to help diagnose and manage gastrointestinal and other health conditions. Its offerings are intended for use by physicians, laboratories and consumers, depending on the product. The company’s principal product is inFoods IBS, a blood-based diagnostic and therapeutic system designed to identify foods that may contribute to symptoms associated with irritable bowel syndrome. The system is intended to support a personalized dietary program under the direction of a healthcare professional.
About Anteris Technologies Global
Anteris Technologies Global is a medical technology company focused on developing treatments for structural heart disease, particularly aortic valve conditions. Its work centers on transcatheter heart valve technology, which is designed to replace a damaged valve through a minimally invasive procedure. The company’s lead product is the DurAVR transcatheter heart valve. It is made using Anteris’ ADAPT tissue technology, which processes bovine pericardial tissue for use in medical devices. The valve is designed to resemble the structure and function of a healthy aortic valve.
Receive News & Ratings for Biomerica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biomerica and related companies with MarketBeat.com's FREE daily email newsletter.
